https://abbim.com/index.php/gr....aphene-based-resourc
The ROS1 fusion kinase is an appealing antitumor target. Though with significant clinical effectiveness, the well-known first-generation ROS1 inhibitor (ROS1i) crizotinib inevitably created obtained resistance as a result of secondary point mutations within the ROS1 kinase. Novel ROS1is effective against mutations conferring additional crizotinib opposition, specifically G2032R, are urgently needed. In the present research, we evaluated the antitumor effectiveness of SAF-
Like
Comment
Share
